With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.215798-19-9,6-Bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride,as a common compound, the synthetic route is as follows.
To a solution of 6-bromo- I ,2,3,4-tetrahydroisoquinoline hydrochloride (2.8 g, 11.3 mmol) inMeCN (50 mL) was added benzyl bromide (2.1 g, 12.4 mmol) and Cs2CO3 (11.1 g, 33.9 mmol).After addition, the resulting mixture was heated at reflux for I h. The solvent was evaporatedunder reduced pressure and the residue was dissolved in ethyl acetate (100 mL). The solutionwas then washed with brine (100 mL), dried (Na2SO4) and concentrated under reduced pressure. The crude product was purified by silica-gel chromatography (petroleum ether: ethyl acetate = 10:1) to give the title compound (2.7 g, 79% yield) as a colourless oil.
As the paragraph descriping shows that 215798-19-9 is playing an increasingly important role.
Reference£º
Patent; GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC.; ALBRECHT, Brian, K.; COTE, Alexandre; GEHLING, Victor; HSIAO-WEI TSUI, Vickie; KIEFER, James, Richard, Jr.; LIANG, Jun; MAGNUSON, Steven; NASVESCHUK, Christopher, G.; PASTOR, Richard; ROMERO, F. Anthony; TAYLOR, Alexander, M.; ZHANG, Birong; (287 pag.)WO2016/112284; (2016); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem